posted on 2023-06-02, 21:43authored byTanner
J. Schubert, Edmund Oboh, Hannah Peek, Emily Philo, José E. Teixeira, Erin E. Stebbins, Peter Miller, Jonathan Oliva, Francis M. Sverdrup, David W. Griggs, Christopher D. Huston, Marvin J. Meyers
Our previous work identified compound 1 (SLU-2633)
as a potent lead compound toward the identification of a novel treatment
for cryptosporidiosis, caused by the parasite Cryptosporidium (EC50 = 0.17 μM). While this compound is potent
and orally efficacious, the mechanism of action and biological target(s)
of this series are currently unknown. In this study, we synthesized
70 compounds to develop phenotypic structure–activity relationships
around the aryl “tail” group. In this process, we found
that 2-substituted compounds are inactive, confirmed that electron
withdrawing groups are preferred over electron donating groups, and
that fluorine plays a remarkable role in the potency of these compounds.
The most potent compound resulting from this work is SLU-10482 (52, EC50 = 0.07 μΜ), which was found
to be orally efficacious with an ED90 < 5 mg/kg BID
in a Cryptosporidium-infection mouse model, superior
to SLU-2633.